ArticleCancer prevention research (Philadelphia, Pa.)2016
Inflammation-Related IL1β/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma.
Article in Cancer prevention research (Philadelphia, Pa.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 87 citations in OpenAlex.
- Pathobiology and clinical significance of malignant pleural effusions.EMBO molecular medicine · 2026Review
- Molecular Characterization of Pericardial Mesothelioma With Constrictive and Recurrent Pericarditis: TAZ Amplification and Hippo Pathway.JACC. Case reports · 2025Article
- [Research Progress on Interleukin-6 in Screening and Prognosis of Patients with Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma.Cancer research communications · 2025Article
- Unveiling the link between chronic inflammation and cancer.Metabolism open · 2025Review
- Comparison of various methodological approaches to model asbestos thresholds for mesothelioma.Frontiers in public health · 2025Review
- Modeling Malignant Mesothelioma in Genetically Engineered Mice.Current protocols · 2025Article
- Cellular defense mechanisms against asbestos fibers.Frontiers in public health · 2025Review
- Review
- Potential New Inflammatory Markers in Bronchiectasis: A Literature Review.Current issues in molecular biology · 2024Review
- Low Exposures to Amphibole or Serpentine Asbestos in Germline Bap1-mutant Mice Induce Mesothelioma Characterized by an Immunosuppressive Tumor Microenvironment.Cancer research communications · 2024Article
- Review
- Targeting inflammatory factors for chemoprevention and cancer interception to tackle malignant mesothelioma.Oncoscience · 2024Article
- Review
- Review
- Inflammation as a chemoprevention target in asbestos-induced malignant mesothelioma.Carcinogenesis · 2022Article
- Understanding exposures and latent disease risk within the National Institute of Environmental Health Sciences Superfund Research Program.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- KRAS signaling in malignant pleural mesothelioma.EMBO molecular medicine · 2022Article
- Tumor accomplice: T cell exhaustion induced by chronic inflammation.Frontiers in immunology · 2022Review
- Late Inflammation Induced by Asbestiform Fibers in Mice Is Ameliorated by a Small Molecule Synthetic Lignan.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Exposure to asbestos is causally associated with the development of malignant mesothelioma, a cancer of cells lining the internal body cavities. Malignant mesothelioma is an aggressive cancer resistant to all current therapies. Once inhaled or ingested, asbestos causes inflammation in and around tissues that come in contact with these carcinogenic fibers. Recent studies suggest that inflammation is a major contributing factor in the development of many types of cancer, including malignant mesothelioma. The NALP3/NLRP3 inflammasome, including the component ASC, is thought to be an important mediator of inflammation in cells that sense extracellular insults, such as asbestos, and activate a signaling cascade resulting in release of mature IL1β and recruitment of inflammatory cells. To determine if inflammasome-mediated inflammation contributes to asbestos-induced malignant mesothelioma, we chronically exposed Asc-deficient mice and wild-type littermates to asbestos and evaluated differences in tumor incidence and latency. The Asc-deficient mice showed significantly delayed tumor onset and reduced malignant mesothelioma incidence compared with wild-type animals. We also tested whether inflammation-related release of IL1β contributes to tumor development in an accelerated mouse model of asbestos-induced malignant mesothelioma. Nf2(+/-);Cdkn2a(+/-) mice exposed to asbestos in the presence of anakinra, an IL1 receptor (IL1R) antagonist, showed a marked delay in the median time of malignant mesothelioma onset compared with similarly exposed mice given vehicle control (33.1 weeks vs. 22.6 weeks, respectively). Collectively, these studies provide evidence for a link between inflammation-related IL1β/IL1R signaling and the development of asbestos-induced malignant mesothelioma. Furthermore, these findings provide rationale for chemoprevention strategies targeting IL1β/IL1R signaling in high-risk, asbestos-exposed populations. Cancer Prev Res; 9(5); 406-14. ©2016 AACR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.